Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:32 pm Sale |
2024-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
Nantahala Capital Management, LLC | 2,340,333 4.380% |
-583,688 (-19.96%) |
Filing History |
| 2025-02-12 09:32 am Purchase |
2024-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
Adage Capital Management L.P. | 3,650,000 6.840% |
3,650,000 (New Position) |
Filing History |
| 2025-02-05 1:23 pm Purchase |
2024-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
BLACKROCK INC BLK |
4,080,420 7.600% |
1,670,131 (+69.29%) |
Filing History |
| 2024-11-14 4:53 pm Purchase |
2024-09-30 | 13G | Zevra Therapeutics, Inc. ZVRA |
Nantahala Capital Management, LLC | 2,924,021 5.557% |
470,616 (+19.18%) |
Filing History |
| 2024-11-14 1:00 pm Purchase |
2024-09-30 | 13G | Zevra Therapeutics, Inc. ZVRA |
Woodline Partners LP | 4,048,653 7.700% |
4,048,653 (New Position) |
Filing History |
| 2024-11-12 5:59 pm Unchanged |
2024-09-30 | 13G | Zevra Therapeutics, Inc. ZVRA |
The Vanguard Group | 2,756,061 5.230% |
0 (Unchanged) |
Filing History |
| 2024-11-04 2:15 pm Purchase |
2024-09-30 | 13G | Zevra Therapeutics, Inc. ZVRA |
The Vanguard Group | 2,756,061 5.230% |
2,756,061 (New Position) |
Filing History |
| 2024-02-14 4:51 pm Purchase |
2023-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
Nantahala Capital Management, LLC | 2,453,405 6.200% |
2,453,405 (New Position) |
Filing History |
| 2024-01-29 5:25 pm Purchase |
2023-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
BLACKROCK INC BLK |
2,410,289 5.800% |
1,557,440 (+182.62%) |
Filing History |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Zevra Therapeutics, Inc. ZVRA |
BLACKROCK INC BLK |
852,849 2.500% |
-1,382,693 (-61.85%) |
Filing History |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
BLACKROCK INC BLK |
2,235,542 6.300% |
2,235,542 (New Position) |
Filing History |
| 2022-01-12 4:03 pm Sale |
2022-01-04 | 13G | Zevra Therapeutics, Inc. ZVRA |
Braun Samuel J | 3,021,660 8.600% |
-355,900 (-10.54%) |
Filing History |
| 2022-01-11 10:30 am Sale |
2021-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
Empery Asset Management, LP | 801,670 2.220% |
-428,330 (-34.82%) |
Filing History |
| 2021-12-01 08:25 am Purchase |
2021-11-30 | 13D | Zevra Therapeutics, Inc. ZVRA |
Braun Samuel J | 3,377,560 9.600% |
222,560 (+7.05%) |
Filing History |
| 2021-05-17 4:43 pm Purchase |
2021-05-10 | 13G | Zevra Therapeutics, Inc. ZVRA |
Braun Samuel J | 3,155,000 11.100% |
1,098,500 (+53.42%) |
Filing History |
| 2021-04-19 5:12 pm Purchase |
2021-04-09 | 13G | Zevra Therapeutics, Inc. ZVRA |
Braun Samuel J | 2,056,500 7.200% |
2,056,500 (New Position) |
Filing History |
| 2021-03-09 10:38 am Purchase |
2020-12-31 | 13G | KemPharm, Inc. KMPH |
Mangless Daniel John | 700,000 3.700% |
575,000 (+460.00%) |
Filing History |
| 2021-02-16 07:01 am Purchase |
2020-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
Delaware Street Capital Master Fund L.P. | 159,364 3.400% |
159,364 (New Position) |
Filing History |
| 2021-02-12 2:23 pm Sale |
2021-02-08 | 13G | Zevra Therapeutics, Inc. ZVRA |
Auctus Fund LLC | 450,000 2.380% |
-550,000 (-55.00%) |
Filing History |
| 2021-02-11 8:14 pm Purchase |
2020-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA |
Mickle Travis C | 227,545 4.900% |
227,545 (New Position) |
Filing History |